BHVN Biohaven Ltd.
Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $635.07M | $795.87M | $373.28M | $437.07M | $181.49M |
| SG&A expense | $110.31M | $89.24M | $62.77M | $130.86M | $37.41M |
| Operating income | -$745.38M | -$885.11M | -$436.05M | -$567.93M | -$218.90M |
| Pretax income | -$737.38M | -$845.69M | -$409.55M | -$569.84M | -$212.43M |
| Income tax | $1.44M | $735,000 | -$1.38M | $438,000 | $1.37M |
| Net income | -$738.82M | -$846.42M | -$408.17M | -$570.28M | -$213.80M |
| EBITDA | -$735.46M | -$877.26M | -$429.14M | -$566.55M | -$217.51M |
| EPS (basic) | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 |
| EPS (diluted) | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 |
| Weighted avg. shares (diluted) | 107.62M | 91.23M | 71.20M | 44.74M | 39.38M |
| Balance sheet | |||||
| Cash & equivalents | $229.96M | $102.54M | $248.40M | $242.60M | $77.06M |
| Short-term investments | $89.18M | $386.86M | $133.42M | $260.46M | $0 |
| Current assets | $368.33M | $538.47M | $442.45M | $586.97M | $94.82M |
| PP&E, net | $15.96M | $17.32M | $17.19M | $17.51M | $13.01M |
| Goodwill | $1.39M | $1.39M | $1.39M | $1.39M | $1.39M |
| Intangibles | $18.40M | $18.40M | $18.40M | $18.40M | $18.40M |
| Total assets | $451.45M | $615.11M | $513.21M | $661.78M | $142.06M |
| Current liabilities | $115.93M | $154.23M | $55.42M | $90.02M | $41.94M |
| Total liabilities | $399.38M | $191.67M | $85.24M | $123.01M | $47.37M |
| Shareholders' equity | $52.07M | $423.44M | $427.98M | $538.77M | $34.69M |
| Shares outstanding | 132.78M | 101.22M | 81.12M | 68.19M | 0 |
| Cash flow statement | |||||
| Operating cash flow | -$609.44M | -$582.45M | -$331.73M | -$297.69M | -$145.84M |
| Capital expenditure | $715,000 | $4.05M | $3.05M | $6.07M | $938,000 |
| Free cash flow | -$610.15M | -$586.50M | -$334.77M | -$303.76M | -$146.78M |
| Investing cash flow | $300.56M | -$244.97M | $129.83M | -$304.79M | $944,000 |
| Financing cash flow | $439.12M | $677.77M | $211.91M | $767.60M | $138.45M |
| Depreciation & amortization | $9.92M | $7.86M | $6.91M | $1.39M | $1.39M |
| Stock-based compensation | $112.36M | $71.96M | $28.79M | $193.56M | $65.64M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.